Lysosomal Therapeutics

19 Blackstone Street
Cambridge
Massachusetts
02139
United States

Email: Info@LysosomalTx.com

Show jobs for this employer

About Lysosomal Therapeutics

Lysosomal Therapeutics Inc. (LTI) is dedicated to innovative small-molecule research and development in the field of neurodegeneration, yielding new treatment options for patients with severe neurological diseases. Our strategy leverages the clinically-validated link between lysosome-based genetic disorders and neurodegenerative diseases to establish a unique and effective molecular platform for novel drug discovery. LTI’s lead program targets Gaucher-related neurodegeneration, Parkinson’s disease and other synucleinopathies.
YEAR FOUNDED:
2014
LEADERSHIP:
Founders: Dimitri Krainc, Joseph Mazzulli, Henri Termeer, Peter Wirthand, Peter Wirth, Bob Carpenter, and Kees Been
Founder and CEO: Kees Been
CFO: Daniel Geffken
CSO: Peter Lansbury

2 articles with Lysosomal Therapeutics